OCREVUS is a medicine that represents a different scientific approach to treating multiple sclerosis. It targets a type of immune cell called CD20-positive B cell that plays a key role in the disease.
OCREVUS is approved for use in relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in countries across North America, South America, the Middle East, Europe, as well as in Australia. In Canada, OCREVUS is approved for only relapsing-remitting multiple sclerosis in adults with active disease. OCREVUS is administered by intravenous infusion every six months, with no routine testing between dosing.
OCREVUS was designated Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and approved by the FDA in March 2017 and by the European Commission in January 2018.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.